4D Molecular Therapeutics, Inc. (FDMT) Stock Grade

About 4D Molecular Therapeutics, Inc.'s fundamentals

4D Molecular Therapeutics is a biotechnology company with a market capitalization of $761.1 million that reported extraordinary revenue growth of over 230,000% year-over-year, though this reflects early-stage commercial activity from a very small base. The company is currently unprofitable with a net margin of -164.4% and posted a net loss in its latest annual statement, which is typical for development-stage biotech firms investing heavily in research and bringing new therapeutics to market. The company does not pay a dividend, and traditional valuation metrics like P/E ratio and return on equity are not meaningful given the loss-making status.